118 related articles for article (PubMed ID: 10537439)
1. Lamivudine reduces healthcare resource use when added to zidovudine-containing regimens in patients with HIV infection.
Lacey L; Gill MJ
Pharmacoeconomics; 1999; 15 Suppl 1():13-22. PubMed ID: 10537439
[TBL] [Abstract][Full Text] [Related]
2. A prospective evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing antiretroviral treatment regimens in HIV infection. European perspective.
Lacey L; Youle M; Trueman P; Staszewski S; Schrappe M; Behrens M
Pharmacoeconomics; 1999; 15 Suppl 1():39-53. PubMed ID: 10537441
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing regimens in HIV infection. Canadian perspective.
Lacey L; Hopkinson PK; Montaner J; Leblanc F; Gill MJ
Pharmacoeconomics; 1999; 15 Suppl 1():55-66. PubMed ID: 10537442
[TBL] [Abstract][Full Text] [Related]
4. A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regimens for HIV infection in the US.
Lacey L; Mauskopf J; Lindrooth R; Pham S; Saag M; Sawyer W
Pharmacoeconomics; 1999; 15 Suppl 1():23-37. PubMed ID: 10537440
[TBL] [Abstract][Full Text] [Related]
5. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.
Lancet; 1997 May; 349(9063):1413-21. PubMed ID: 9164314
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
Sánchez-de la Rosa R; Herrera L; Moreno S
Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
[TBL] [Abstract][Full Text] [Related]
7. Quality of life and treatment satisfaction after the addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens in treatment-experienced patients with HIV infection.
Chatterton ML; Scott-Lennox J; Wu AW; Scott J
Pharmacoeconomics; 1999; 15 Suppl 1():67-74. PubMed ID: 10537443
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates.
Mauskopf J; Lacey L; Kempel A; Simpson K
Am J Manag Care; 1998 Jul; 4(7):1004-12. PubMed ID: 10181990
[TBL] [Abstract][Full Text] [Related]
9. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
Gulick RM; Mellors JW; Havlir D; Eron JJ; Gonzalez C; McMahon D; Richman DD; Valentine FT; Jonas L; Meibohm A; Emini EA; Chodakewitz JA
N Engl J Med; 1997 Sep; 337(11):734-9. PubMed ID: 9287228
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial.
Petra Study Team
Lancet; 2002 Apr; 359(9313):1178-86. PubMed ID: 11955535
[TBL] [Abstract][Full Text] [Related]
11. Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection.
Perry CM; Faulds D
Drugs; 1997 Apr; 53(4):657-80. PubMed ID: 9098665
[TBL] [Abstract][Full Text] [Related]
12. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
Brogan AJ; Talbird SE; Cohen C
Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
[TBL] [Abstract][Full Text] [Related]
14. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA
N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227
[TBL] [Abstract][Full Text] [Related]
15. [Simplification to lamivudine, zidovudine, and abacavir therapy: impact on adherence, clinical outcome, and economic issues].
Ibarra Barrueta O; Martínez Bengoechea MJ; Illaro Uranga A; Lertxundi Etxebarría U; Iglesias Lambarri A; Santos Ibáñez A
Farm Hosp; 2004; 28(6 Suppl 1):27-33. PubMed ID: 15649113
[TBL] [Abstract][Full Text] [Related]
16. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team.
Havlir DV; Marschner IC; Hirsch MS; Collier AC; Tebas P; Bassett RL; Ioannidis JP; Holohan MK; Leavitt R; Boone G; Richman DD
N Engl J Med; 1998 Oct; 339(18):1261-8. PubMed ID: 9791141
[TBL] [Abstract][Full Text] [Related]
17. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy.
Hirsch M; Steigbigel R; Staszewski S; Mellors J; Scerpella E; Hirschel B; Lange J; Squires K; Rawlins S; Meibohm A; Leavitt R
J Infect Dis; 1999 Sep; 180(3):659-65. PubMed ID: 10438352
[TBL] [Abstract][Full Text] [Related]
18. AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients. AVANTI Study Group.
Gatell J; Lange J; Gartland M
Antivir Ther; 1999; 4(2):79-86. PubMed ID: 10682152
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team.
Pialoux G; Raffi F; Brun-Vezinet F; Meiffrédy V; Flandre P; Gastaut JA; Dellamonica P; Yeni P; Delfraissy JF; Aboulker JP
N Engl J Med; 1998 Oct; 339(18):1269-76. PubMed ID: 9791142
[TBL] [Abstract][Full Text] [Related]
20. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial.
Cook J; Dasbach E; Coplan P; Markson L; Yin D; Meibohm A; Nguyen BY; Chodakewitz J; Mellors J
AIDS Res Hum Retroviruses; 1999 Apr; 15(6):499-508. PubMed ID: 10221527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
